Navigation Links
Caprion Awarded US $12.9M Infectious Disease Biomarker Research Contract
Date:10/6/2008

MONTREAL, Oct. 6 /PRNewswire/ -- Caprion Proteomics Inc. announced today that it has been awarded a $12.9 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the US National Institutes of Health, to carry out Biodefense research in the area of infectious disease biomarkers.

Under the contract to be performed over a five-year period, Caprion will act as one of two NIAID Clinical Proteomics Centers for Infectious Disease & Biodefense, and will employ its distinctive CellCarta(R) quantitative protein profiling technologies to perform several large scale applied proteomics projects using human clinical samples from patients with infectious diseases. The projects will be aimed at the discovery, qualification, and verification of candidate biomarkers with potential for clinical use to improve detection and diagnosis and to monitor therapeutic and vaccine responses and susceptibility to infection for diseases caused by various pathogens. This second major Biodefense research contract awarded to Caprion by NIAID builds on the expertise and results demonstrated by Caprion as part of an initial contract awarded in 2004 and still in progress.

"We are very pleased to be granted the opportunity to expand our infectious disease research program with NIAID into the area of clinical biomarker discovery and validation," said Martin LeBlanc, President and CEO at Caprion. "This second major contract award from the NIAID provides further evidence of Caprion's solid scientific capabilities and industry leadership position as a proteomics and biomarker services provider."

Caprion will retain rights to commercialize candidate biomarkers and diagnostic products discovered in this project.

About Caprion Proteomics, Inc.

Caprion Proteomics is the leading provider of proteomics based services to the pharmaceutical industry. Caprion's proprietary proteomics discovery technology, CellCarta(R), is a gel-free,
'/>"/>

SOURCE Caprion Proteomics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. SpectraScience Awarded Patent for Its Optical Biopsy System and Methods for Tissue Diagnosis
2. Matthew B. Wiener, CEO of Pharmatech, Inc., Is Awarded the Cancer Leadership Award From the Colorado Cancer Coalition
3. GeneGo Is Awarded NCI Grant for Development of Systems Biology Database and Tools for Nutrition in Cancer in Collaboration with the FDA
4. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
5. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
6. eGenomics Awarded First U.S. Patent Covering Rapid DNA Sequencing Technology Platform to Control Hospital-Acquired Infections
7. Dr. Yong Shi awarded NSF grant
8. Advanced Life Sciences Awarded U.S. Department of Defense Biodefense Contract Valued at up to $3.8 Million
9. BioNanomatrix Awarded New NIH Grant for Development of Nanoscale Platform for Single-Molecule DNA Mapping and Haplotype Applications
10. U.S. Genomics Awarded $9.1 Million Contract for Development of Advanced Biosensor by the U.S. Department of Homeland Security
11. ImQuest Awarded SBIR Grant to Define the Mechanism of Action of Their Lead Anti-HIV Therapeutic Compound IQP-0410
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... and Companies" to their offering. ... variations, development of sequencing technologies, and their applications. ... well as companies developing them. Various applications of ...
(Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cqsxmg/gene_therapy ) ... "Gene Therapy - Technologies, Markets and Companies" ... therapy are difficult to estimate as there is only ... in China since 2004. Gene ... estimates are based on epidemiology of diseases to be ...
(Date:9/2/2015)... 2, 2015  Neurotech Pharmaceuticals, Inc., announced today ... multicenter Phase 2 clinical trial of NT-503 Encapsulated ... recurrent subfoveal choroidal neovascularization secondary to age related ... vascular endothelial growth factor (VEGF) receptor protein continuously ... "This landmark proof-of-concept study will evaluate NT-503 ECT ...
(Date:9/2/2015)... , September 2, 2015 ... BOLT) ("BioLight" or the "Company"), a firm that ... ophthalmology and cancer diagnostics, announced today that presentations ... glaucoma will be delivered at the Ophthalmology Futures ... European Society of Cataract & Refractive Surgeons ("ESCRS"), ...
Breaking Biology Technology:Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2Global Gene Therapy Market Study 2015-2024 - Technologies, Markets and Companies Analysis 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... Project is Aimed at Developing New Screening Methods and Holds Significant, Potential ... ... Killer, - Biomarker Project holds significant potential for ... detect the disease before ...
... in 24 European ... Countries, - Competitors Precluded from Immediate Commercialization of ... ... &,Bioressources Inc. ("Neptune") (NASDAQ.NEPT - TSX.V.NTB) announces that the,European Patent Office (EPO) granted on ...
... to Aida Pharmaceuticals, ... Inc.,s Product ... (OTC Bulletin Board: AIDA) today announced that it,has signed two ... the leading microbiology research institutes in the People,s,Republic of China, ...
Cached Biology Technology:Lustgarten Foundation Announces $1.25 Million Commitment to Pancreatic Cancer Biomarker Development Project 2Lustgarten Foundation Announces $1.25 Million Commitment to Pancreatic Cancer Biomarker Development Project 3Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications 2Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications 3Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the People's Republic of China 2Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the People's Republic of China 3
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors ... growth in applications, penetration into newer sectors, and development ... The global biosensors space has seen the entry of ... market so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ... Sullivan, Analysis of the Global Biosensors Market ...
(Date:8/4/2015)... N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today ... 30, 2015. Highlights: , Second quarter contract ... from 2014 , Adjusted contract margins of ... of $0.22, including a $0.05 decrease in EPS from royalties in ... $16 million "We are very pleased to present ...
(Date:7/31/2015)... 31. juli 2015 Den 10. internationale konference ... BGI fra den 22. - 25. oktober i ... sin 10-års fødselsdag i år. Siden starten i 2006 ... møder på ,omik,-feltet, og er en af de mest ... ICG-10 fokuserer på nylige gennembrud og fremskridt inden for ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... A team of international molecular scientists, led by a ... which cells communicate change for example their location during ... adjacent cells. The discovery sheds new light on cell ... to combat diseases such as cancer, rheumatoid arthritis and Alzheimer,s ...
... the behaviour of invasive ants in northern Australia, finding ... networks, CSIRO has recognised the outstanding work of some ... in Melbourne. The CSIRO Medals are awarded each year ... contributions to the organisation. Awarded since 1985, the CSIRO ...
... of altruism has long puzzled researchers and has mainly ... now because I expect there to be some long-term ... at the Primate Research Institute (PRI) and the Wildlife ... altruistically help conspecifics, even in the absence of direct ...
Cached Biology News:Milestone discovery in cell behaviors 2CSIRO medal winners 2CSIRO medal winners 3Chimpanzees help each other on request but not voluntarily 2
...
... antibody recognizes 30% of IgM-rheumatoid ... It does not cross-react with IgM, ... factor nor with pooled F(Ab)2 fragments. ... ELISA to detect rheumatoid factor. Product ...
... ,human IgG subclass 1 100% ,human IgG subclass ... 100% ,human IgG subclass 4 ... 100% ,human IgG Fc ... 0.04% ,human IgG Fab ...
...
Biology Products: